Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

This study compares two chemotherapy regimens — tislelizumab plus FOLFOX versus POF — in people with advanced stomach or stomach-esophagus junction cancer that cannot be surgically removed or has spread. Both regimens combine immunotherapy with chemotherapy. **You may be eligible if...** - You are 18–70 years old with confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction - You have not received prior chemotherapy, radiation, or immunotherapy for this cancer - Your blood counts and organ function are adequate - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have already received treatment for this cancer - You have a history of heart failure - Your blood counts or organ function do not meet the requirements Talk to your doctor to see if this trial is right for you.